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Summary. Meta-hydroxyephedrine (HED) comprises four stereoisomers con-
sisting of two enantiomeric pairs related to ephedrine and pseudoephedrine.
HED is transported into adrenergic neurons and radiolabeled HED has been
employed in positron emission tomography (PET) to image adrenergic neu-
rons in vivo. To extend structure-activity analyses of binding sites within
monoamine transporters and to determine which stereoisomer displayed the
best selectivity for PET imaging applications, we tested the HED compounds
for their abilities to inhibit [3H]neurotransmitter uptake into platelets,
transfected cells, and chromaffin vesicles. We hypothesized that the HED
compounds would be most potent at the norepinephrine transporter (NET)
compared to the serotonin or dopamine transporters and that the 1R diaste-
reomers would be more effective than 1S diastereomers. Supporting the
hypotheses, all stereoisomers were most potent at the NET and the 1R,2S
stereoisomer was the most potent inhibitor overall. However, the 1S,2R iso-
mer may be preferred for PET applications because of better selectivity
among the transporters and reduced neuronal recycling.
Keywords: m-hydroxyephedrine, dopamine transporter (DAT), norepineph-
rine transporter (NET), serotonin transporter (SERT), vesicle monoamine
transporter (VMAT2), positron emission tomography (PET), stereoisomer,
substrate, noradrenaline.
Introduction
Following their release as chemical neurotransmitters, the biogenic amines
serotonin, dopamine, and norepinephrine are cleared from the synapse
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via their respective sodium- and chloride-dependent plasma membrane
uptake transporters SERT, DAT, and NET. These transporters belong
to a large family of uptake carriers with common structural features (Graham
and Langer, 1992; Rudnick and Clark, 1993; Kanner, 1994; Worrall and
Williams, 1994), but the SERT, DAT, and NET differ in their substra-
te:ion stoichiometry (Rudnick, 1998). The transporters also differ in their
substrate selectivity, inhibitor sensitivity, and transport kinetics (Gu et al.,
1994). Once the biogenic amines have been translocated into the neuron by
the plasma membrane transporters, they are packaged into synaptic vesicles
by the neuronal vesicle transporter VMAT2 (Feany et al., 1992; Liu et al.,
1992). Like the plasma membrane carriers, VMAT2 is predicted to have 12
transmembrane domains (TMDs), with cytosolic amino and carboxy termini.
Unlike the plasma membrane carriers, VMAT2 does not require sodium
or chloride ions. Rather, the influx of neurotransmitter into the vesicle is
coupled to the efflux of protons; the vesicle is supplied with protons through
the action of a vesicle membrane ATP-driven proton pump (Njus, 1983;
Johnson, 1987).
In addition to translocating their respective biogenic amines, the monoam-
ine uptake transporters will also translocate certain exogenous compounds.
These compounds include phenylalkylamines such as metaraminol, 3,4-
methylenedioxymethamphetamine (MDMA), and fenfluramine (Schuldiner
et al., 1993; Crespi et al., 1997; Rothman et al., 1999). The fact that the
monoamine transporters can tolerate some structural diversity among sub-
strates has been exploited in the development of drugs that can act as surro-
gates for the biogenic amines. Meta-hydroxyephedrine (HED), for example,
is a catecholamine substrate analog that is accumulated within adrenergic
neurons via the NET (Rosenspire et al., 1990). HED comprises two enantio-
meric pairs related to ephedrine (erythro configuration) or pseudoephedrine
(threo configuration) (Fig. 1). A radiolabeled form of one of the stereoiso-
mers, 1R,2S [11C]HED, has been employed as a positron emission tomogra-
phy (PET) tracer to image adrenergic neurons in vivo. 1R,2S [11C]HED was
used to study the NET-mediated neuronal uptake kinetics of cardiac adrener-
gic terminals in an experimental model of ischemia, in disease states such as
myocardial infarction and diabetic neuropathy, and in transplanted human
heart (Schwaiger et al., 1991; Allman et al., 1993a,b; DeGrado et al., 1993; Di
Carli et al., 1997).
Our laboratory employs structure-activity relationship studies of
monoamine transporter substrate analogs as one approach to characterizing
drug binding sites within these carrier proteins. Through their ability to com-
petitively inhibit the uptake of endogenous neurotransmitters, substrate ana-
logs can reveal whether the monoamine carriers prefer certain structural
features; these preferences are indicative of the biochemical microenviron-
ment within the substrate binding sites of the transporters. HED is well-suited
to these kinds of studies because HED comprises four stereoisomers that have
identical chemical structures but differ only in the three-dimensional configu-
ration of the amino and hydroxyl groups on the alkylamine side-chain (Fig. 1).
Any observed differences in potency among the HED isomers will indicate
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what parts of the ligand are important for molecular recognition by the
transporters and will reflect the geometry of the substrate binding pocket
within the transporters. Due to the current unavailability of the crystal
structure of the transporters, this approach allows one to construct
pharmacophore-based models of the substrate binding sites. These models
have predictive power in drug design and must ultimately be in harmony
with the three-dimensional structures of the transporters, if they are
solved.
To extend our structure-activity studies of monoamine transporter ligands
and to determine which of the HED isomers displays the best transporter
selectivity for PET imaging applications, all four stereoisomers of HED were
synthesized and tested for their abilities to inhibit monoamine neurotransmit-
ter uptake in vitro. Among the plasma membrane uptake transporters, we
hypothesized that the HED compounds would be most potent at the NET
because of their structural similarity to norepinephrine. We further hypoth-
esized that the 1R diastereomers would be more potent than the 1S diastere-
omers because norepinephrine itself has R stereochemistry at this position.
To test for selectivity among the monoamine transporters, we examined the
ability of each of the HED isomers to inhibit tritiated monoamine uptake into
human platelets (SERT) or cultured cells individually expressing the cloned
human DAT or NET. We also tested the HED isomers for the ability to
inhibit [3H]serotonin uptake into bovine chromaffin vesicles via VMAT2. By
comparing the IC50 values for monoamine uptake inhibition among the four
stereoisomers, we hoped to identify structure-related differences in potency
and selectivity among the monoamine transporters. In this study, we were
able to detect such differences among the HED isomers. These observations
should aid in modeling the transporter substrate binding sites and in the
rational design of transporter-selective drugs for imaging studies and new
drugs to treat diseases, such as depression, which have been associated with
aberrant transporter function.
Fig. 1. Chemical structures of meta-hydroxyephedrine stereoisomers
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Materials and methods
Drugs and reagents
The chemical synthesis of the four HED isomers has been reported previously by one of
us (Van Dort and Tluczek, 2000). Briefly, a mixture containing the four stereoisomers of
meta-hydroxyphenylpropanolamine (MHPA) was synthesized in 20% overall yield by a
seven-step synthetic route from propiophenone. The individual MHPA stereoisomers
were isolated from the mixture using semipreparative chiral high pressure liquid chroma-
tography (HPLC) as described (Van Dort, 1999). Each stereoisomer of MHPA was
converted to its respective carbamate derivative, which was then reduced to the respec-
tive HED stereoisomer with lithium aluminum hydride in refluxing tetrahydrofuran.
After chromatographic purification, the HED free bases were converted to the hydro-
chloride salts and recrystalized. The HED isomers were characterized with respect to
their physical properties by melting point (Thomas Hoover apparatus) and optical rota-
tion (Perkin-Elmer 241 polarimeter; 589 nm) determinations. Chemical structures were
confirmed by 1H NMR spectroscopy (Bruker WM-360; 360MHz) and by high-resolution
mass spectrometry (Finnigan UG70-250-S). For uptake inhibition assays, 10mM stock
solutions of the HED isomers were individually prepared in deionized water.
[2H]Serotonin (specific activity  36.4Ci/mmol), [3H]dopamine (specific activity 
59.1 Ci/mmol), and [3H]norepinephrine (specific activity  55.0Ci/mmol) were purchased
from New England Nuclear, Boston, MA. Cell culture media and antibiotics were
purchased from Life Technologies, Gaithersburg, MD. Fetal bovine serum was obtained
from Hyclone, Logan, UT. Pargyline, reserpine, buffer salts, and miscellaneous chemicals
were acquired from Aldrich Chemical, Milwaukee, WI.
Serotonin plasma membrane uptake transporter: [3H]serotonin uptake into
human platelets
To test drug effects on SERT-mediated [3H]serotonin accumulation, human donor plate-
lets were used. Outdated platelets were obtained from the blood bank at Pitt County
Memorial Hospital, Greenville, NC. Platelets were prepared for uptake assays as previ-
ously described (Cozzi et al., 1999). After two washes, the final pellet was suspended in
30 ml ice-cold Krebs-Ringer-HEPES (KRH) buffer containing (mM): NaCl (124.0), KCl
(2.9), MgSO4 (1.3), KH2PO4 (1.2), CaCl2 (2.4), d-glucose (5.2), HEPES (25.0), sodium
ascorbate (0.1), pargyline (0.1); pH  7.4. The suspension was then stored on ice until use.
For assays, a 490 µl aliquot of the platelet suspension was added to glass tubes containing
either 5µl meta-hydroxyephedrine isomer solution (various concentrations) or 5µl KRH
(for total and nonspecific determinations). The assay tubes were preincubated in a 37°C
shaking water bath for 5 min. The tubes were then returned to the ice bath and chilled for
15 min. [3H]Serotonin was added to each tube (5µl of stock solution; final concentration,
15 nM), giving a total incubation volume of 500µl. All assay tubes except nonspecific tubes
were returned to the 37°C shaking water bath for 5min to initiate neurotransmitter
uptake. Uptake was terminated by chilling the test tubes in the ice bath. After adding 3 ml
ice-cold 150 mM NaCl, each assay tube was vacuum filtered through glass fiber filters
(Whatman GF/B) pretreated with 0.1% polyethyleneimine (PEI). Filters were washed
with 2  3ml ice-cold 150 mM NaCl, allowed to dry briefly under vacuum, then placed in
liquid scintillation vials. Scintillation cocktail (3ml) was added and the vials were sealed,
vortexed, and allowed to stand overnight. Radioactivity was measured using liquid scin-
tillation counting (Packard Tri-Carb 1600 CA). Specific uptake was defined as uptake at
37°C minus uptake at 0°C in the absence of drugs.
Dopamine plasma membrane uptake transporter: [3H]dopamine uptake into
transfected cells
Human embryonic kidney cells stably expressing the human dopamine transporter
(293DAT) were a gift from Dr. M. Reith (University of Illinois). Cells were maintained
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in a humidified atmosphere (5% CO2 in air) in selective culture medium: Dulbecco’s
Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum and antibiotics
(100 U/ml penicillin, 100 µg/ml streptomycin, 2µg/ml puromycin). For assays, the DMEM
was aspirated from 3  100 mm dishes of confluent cells and the cells were washed three
times with 37°C KRH, then harvested in 30 ml total ice-cold KRH. The cells were
suspended using a polytron (setting 4, 5sec). The ability of the test drugs to inhibit
[3H]dopamine uptake was measured as follows: a 490 µl aliquot of the 293DAT cell
suspension was added to glass tubes, then 5µl of meta-hydroxyephedrine isomer (various
concentrations), 5 µl KRH (for total determinations), or 5 µl 10 mM cocaine hydrochlo-
ride (for nonspecific determinations; final concentration, 100µM) was added to the appro-
priate tubes. The tubes were preincubated with shaking at 37°C for 10 min, then returned
to the ice bath and chilled for 15 min. Five µl of [3H]dopamine (final concentration, 15nM)
was added to each tube and the assay tubes were incubated with shaking at 37°C for
10 min to induce neurotransmitter uptake. Uptake was quenched by chilling the test tubes
in the ice bath, then the assay tubes were diluted, filtered, worked-up, and counted as
described for platelets.
Norepinephrine plasma membrane uptake transporter: [3H]norepinephrine
uptake into transfected cells
C6 rat glial cells stably expressing the human norepinephrine transporter (C6NET) were
a gift from Dr. Susan Amara (Oregon Health Sciences University). Cells were maintained
in a humidified atmosphere (5% CO2 in air) in selective culture medium: DMEM contain-
ing 10% fetal bovine serum and antibiotics (100U/ml penicillin, 100µg/ml streptomycin,
100µg/ml geneticin). For assays, the DMEM was removed from 3  100mm dishes of
confluent cells and the cells were washed with phosphate buffered saline, pH  7.1. The
cells were then treated with trypsin/EDTA and split into 24-well plates. This allowed
triplicate assays for total uptake, nonspecific uptake, and six drug concentrations per
plate. Each well contained 1 ml of culture medium. Cells were grown overnight to
confluency. The ability of the HED isomers to inhibit [3H]norepinephrine uptake was
measured as follows: the DMEM was aspirated from the 24-well plates, the cells were
washed with 3  2ml 37°C KRH, and 490µl 37°C KRH was added to each well. This was
followed by the addition of 5 µl KRH (for total determinations), 5 µl 10mM desipramine
(for nonspecific determinations; final concentration, 100µM), or 5 µl of test drug solution.
The plates were preincubated at 37°C for 10min, then 5 µl of [3H]norepinephrine (final
concentration, 15nM) was added to each well to initiate uptake. Uptake was allowed to
proceed for 10 min, then the incubation buffer was discarded and the cells were washed
with 3  2 ml ice-cold KRH. The cells were solubilized in 500µl 37°C 1% sodium dodecyl
sulfate, then the solubilized well contents were transferred to liquid scintillation vials
containing 3ml scintillation cocktail. Radioactivity was measured as described for
platelets.
Vesicular monoamine transporter (VMAT2): [3H]serotonin uptake into bovine
chromaffin granules
Drug effects on VMAT2-mediated [3H]serotonin accumulation were monitored in bovine
chromaffin vesicles. Vesicles were prepared according to our previously reported proce-
dure (Cozzi et al., 1999). For uptake assays, chromaffin vesicle ghosts were diluted in
assay buffer containing (mM): sucrose (300), HEPES (10), ATP (5), MgSO4 (5), pH  7.8
to a final volume of 0.5ml. Assays were performed in triplicate. The samples were
incubated at 37°C for 10min and then cooled on ice for 10 min. [3H]Serotonin was then
added to a final concentration of 20nM and the samples were incubated for 5 min at 37°C
to initiate uptake. Uptake was tested in the absence or presence of the test drugs added
to the assay buffer; nonspecific uptake was defined by 10µM reserpine. After the 5 min
uptake incubation, samples were transferred to an ice bath and collected onto glass fiber
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filters (Whatman GF/B, pretreated with 0.1% PEI) using a Brandel cell harvester (model
M-48T). The filters were washed with 6  1ml ice-cold assay buffer minus ATP and
MgSO4. Filters were transferred to scintillation vials and 10ml scintillation cocktail was
added. Radioactivity was measured as described for platelets.
Data analysis and statistics
All HED isomers were screened for [3H]monoamine uptake inhibition at 30 µM. If at least
one HED compound inhibited uptake by 50% or more at the screening concentration,
the IC50 values  standard error of the mean (S.E.M.) for all four HED isomers were
determined from displacement curves from at least three experiments using six drug
concentrations, each run in triplicate. Data were transformed from dpm to percent
specific uptake and fitted to a four-parameter logistic curve using commercial computer
software. Multiple comparisons of the HED stereoisomer IC50 values were performed
using ANOVA followed by a Student-Newman-Keuhls t-test using commercial computer
software (GraphPad, San Diego, CA) with P  0.05 considered significant.
Results
In C6NET cells, specific [3H]norepinephrine uptake was 90% of total up-
take as defined by 100 µM desipramine. All of the HED stereoisomers passed
our 30 µM screening criterion at the NET. Dose-response curves for drug
inhibition of [3H]norepinephrine uptake are shown in Fig. 2 with IC50 values
summarized in Table 1. The inhibition curves had slope coefficients of unity,
indicating that the HED isomers acted at a single site on the NET. The 1R,2S
isomer was the most potent inhibitor of [3H]norepinephrine accumulation
(P  0.05) with an IC50 value of 0.42  0.04 µM. The 1S,2R and 1S,2S isomers
were intermediate in potency, while the 1R,2R isomer was the least potent
isomer (all P  0.05; see Table 1). Thus, the rank order of potency among the
HED stereoisomers at the NET is: 1R,2S  1S,2S  1S,2R  1R,2R.
Cocaine-sensitive [3H]dopamine uptake was 65% of total uptake in
293DAT cells. Dose-response curves for drug inhibition of [3H]dopamine
uptake were determined after screening at 30µM. Like drug effects at the
Table 1. IC50 values (µM) for drug inhibition of transporter-mediated monoamine uptakea
Drug NET DAT SERTb VMAT2 Selectivity ratios
DAT :NET VMAT2 :NET
1R,2S HED 0.422  0.04 4.34  1.4 30 23.7  2.2 10.3 56.2
1S,2S HED 1.18  0.26 5.60  0.88 30 58.6  6.5 4.7 49.7
1R,2R HED 6.95  1.1 20.8  2.1 30 144  18 3.0 20.7
1S,2R HED 1.03  0.10 43.2  5.7 30 101  11 41.9 98.1
a The ability of test drugs to inhibit [3H]monoamine accumulation was examined as described under
Materials and methods. HED compounds were tested with 6 concentrations, each run in triplicate. The data
from 3–5 experiments were combined and the IC50 values  S.E.M. were calculated by curve fitting. b Percent
inhibition of [3H]serotonin uptake at 30 µM: 1R,2S HED  31.3  6.3%; 1S,2S HED  21.1  7.8%; 1R,2R
HED  14.1  8.3%; 1S,2R HED  no inhibition
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NET, all the DAT inhibition curves had slope coefficients that did not differ
from unity. All of the HED isomers except the 1S,2R configuration exhibited
IC50 values below 30 µM. The 1R,2S and 1S,2S HED configurations were the
most potent (P  0.01) at the DAT and had similar IC50 values (Table 1). The
1R,2R configuration was four-fold less potent (P  0.01) with an IC50 of
20.8  2.1µM. The 1S,2R stereoisomer was the least potent drug in the series
(P  0.01; Table 1). The rank order of potency among the HED isomers at
the DAT is 1R,2S  1S,2S  1R,2R  1S,2R.
The uptake of [3H]serotonin by platelets in the absence of test drugs
was typically  90% specific. None of the test drugs inhibited specific
[3H]serotonin uptake by at least 50% at the 30µM screening concentration, so
IC50 values were not calculated. However, the percent inhibition of specific
[3H]serotonin uptake was calculated. The percent inhibition at 30µM drug
concentration for each isomer is as follows: 1R,2S  31.3  6.3%; 1S,2S  21.1
 7.8%; 1R,2R  14.1  8.3%; 1S,2R  no inhibition. Just as at the NET and
the DAT, the HED isomer with the 1R,2S configuration appeared to be the
most potent inhibitor at the SERT; the rank order of potency of the HED
isomers at the SERT is 1R,2S  1S,2S  1R,2R  1S,2R.
The VMAT2-mediated uptake of [3H]serotonin in chromaffin ghosts was
90% specific as defined by 10µM reserpine. In this system, the 1R,2S HED
isomer was again the most potent inhibitor of uptake (P  0.05) with an IC50
of 23.7  2.2 µM. The remaining drugs were substantially less potent, with IC50
Fig. 2. Drug inhibition of NET-mediated [3H]norepinephrine uptake. The ability of test
drugs to inhibit accumulation of 15nM [3H]norepinephrine was examined in cultured cells
expressing the human NET. Specific uptake was defined by 100µM desipramine. Data are
the mean  S.E.M. of 3–6 determinations, each run in triplicate. Data were fitted to a
four-parameter logistic curve for IC50 determination and plotting
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values as high as 144 µM (Table 1). The rank order of potency at VMAT2 is
therefore 1R,2S  1S,2S  1S,2R  1R,2R.
Discussion
The synthesis of the individual HED stereoisomers on a milligram scale has
allowed us to test these compounds for their inhibition potencies at the
monoamine uptake transporters. In the present study, we compared the abil-
ities of the four stereoisomers of HED to inhibit [3H]monoamine accumu-
lation via the plasma membrane uptake transporters and via VMAT2. We
expected to see differences in potency among the HED isomers at the plasma
membrane transporters due to the different configurations of the side-chain
amine group. Among monoamine ligands, the (protonated) amine nitrogen
has been proposed to form an ionic bond with a conserved aspartate residue
in TMD1 of the plasma membrane transporters (Kitayama et al., 1992; Barker
et al., 1999). We thought that this interaction would be sensitive to the spatial
placement of the amine. Our expectation was borne out at the SERT and
DAT: the stereochemistry of the side-chain amine group dominates the bind-
ing interaction in these transporters. The 2S diastereomers were more potent
than the 2R diastereomers, regardless of the configuration at the 1-position
(Table 1). In addition to a potentially more productive electronic alignment
with the conserved aspartic acid residue, the 2S isomers may also benefit from
a favorable steric environment for binding (e.g. complementary pocket), or
through some combination of these. The stereochemistry at the 1-position
played a lesser, but still significant, role: the 1R diastereomers were more
potent than the 1S diastereomers, once the effect of the 2-position is taken
into account. Thus, despite the absence of stereogenic centers in serotonin
and dopamine, the substrate binding domains within the SERT and DAT
favor certain topological or electronic configurations in ligand side chains.
The fact that the HED isomers, like dopamine, are phenylalkylamines may
partly explain the increased potency among these drugs at the DAT compared
to the SERT; the SERT would be expected to prefer indolealkylamine sub-
strates. Nevertheless, there exist phenylalkylamines that are quite potent
competitive inhibitors of SERT-mediated [3H]serotonin uptake (Huang et al.,
1992; Monte et al., 1993; Crespi et al., 1997).
We hypothesized that the HED compounds would be most potent at the
NET because of their structural similarity to norepinephrine i.e. the HED
isomers and norepinephrine all contain a hydroxyl moiety on the side-chain.
Supporting our hypothesis, each of the HED compounds exhibited higher
affinities for the NET than for any of the other transporters (Table 1). In
particular, the HED compounds were more effective inhibitors at the NET
than at the highly homologous DAT and SERT proteins. A reasonable ex-
planation for this observation stems from the fact that while the NET will
effectively transport both norepinephrine and dopamine, the DAT and SERT
are not efficient transporters of norepinephrine (Pacholczyk et al., 1991; Giros
et al., 1992). We propose that in norepinephrine, the side-chain hydroxyl is an
essential feature in the molecular exclusion of norepinephrine by the DAT
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and the SERT, either through an unfavorable electrostatic interaction involv-
ing the side-chain hydroxyl group or through steric occlusion within the sub-
strate binding site. The HED compounds, like norepinephrine, incorporate a
hydroxyl group at the side-chain 1-position and would therefore be expected
to encounter the same interference at the DAT and SERT as norepinephrine,
leading to the observed higher affinity at the NET compared to the DAT and
the SERT. The presence of the side-chain hydroxyl also imparts chirality to
the carbon at the 1-position, and, in norepinephrine, the stereochemistry is R.
We hypothesized that both of the HED diastereomers with the 1R configura-
tion would more closely mimic norepinephrine and would therefore be the
most potent inhibitors of [3H]norepinephrine uptake. As our data shows, the
most potent inhibitor of [3H]norepinephrine uptake does have 1R stere-
ochemistry. This is the HED isomer with the 1R,2S configuration. This drug
was the most potent inhibitor of monoamine uptake across all the plasma
membrane transporters, and has an IC50 of only 0.42µM at the NET (Table 1).
Continuing the trend observed at the SERT and DAT, the 1R,2S diastere-
omer was also more potent (about 16-fold) than the 1R,2R configuration.
However, the difference in potency between the 2-position isomers is not
manifested in the 1S HED stereopair: when the stereochemistry is 1S, the
configuration at the side-chain 2-position has no effect on affinity at the NET
(1S,2S  1S,2R; Table 1). Furthermore, the 1S diastereomers were less potent
than the 1R,2S isomer but not the 1R,2R isomer. As submitted above, we had
expected both of the 1R compounds to be more “norepinephrine-like” and
therefore more effective than both of the 1S compounds, but this was not the
case. These results suggest that the amino acid residues involved in ligand
side-chain recognition within the NET substrate site may interact with one
another and with the ligand in a complex way. Losses in affinity due to a
suboptimal configuration at one side-chain carbon may be offset by gains in
affinity at the other carbon; modifications to one site on the ligand can induce
changes in affinity that are not simply additive with respect to the other site.
The bovine chromaffin vesicle is a well-accepted model for VMAT2-
mediated uptake into synaptic vesicles. The human and bovine VMAT2 ex-
hibit similar pharmacological profiles for substrates and inhibitors (Schuldiner
et al., 1995), making bovine vesicles useful for studying drugs that act at
VMAT2. In the present study, only the 1R,2S HED isomer displayed half-
maximal inhibition at less than 30µM at VMAT2. As was seen at the DAT
and SERT, the 2S diastereomers were more effective than the 2R diastere-
omers, regardless of the configuration at the 1-position (Table 1), again
suggesting that the substrate binding site is asymmetric even though the
endogenous ligands are not themselves chiral. The low affinity of the HED
compounds at VMAT2 is remarkable because VMAT2 is relatively indis-
criminate with regard to arylalkylamine binding. Many structurally dissimilar
molecules including tryptamine, histamine, serotonin, dopamine, 5-methoxy-
6-methyl-2-aminoindan, 3-methoxy-4-methylamphetamine, methamphet-
amine, and MDMA inhibit VMAT2-mediated neurotransmitter uptake in
the nanomolar to low micromolar range (Rudnick and Wall, 1993; Finn and
Edwards, 1997; Cozzi et al., 1999).
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Our findings have important implications for the design of PET radiotrac-
ers for imaging sympathetic neurons. In clinical studies, 1R,2S [11C]HED
demonstrates a high initial myocardial uptake and a prolonged tissue clear-
ance consistent with a slow turnover of the radiotracer (Schwaiger et al.,
1990). The low tissue clearance of 1R,2S [11C]HED coupled with the short
half-life of carbon-11 (20min) prohibits the accurate determination of 1R,2S
[11C]HED release from nerve terminals and therefore does not permit the
measurement (compartmental modeling) of norepinephrine tissue release
based on 1R,2S [11C]HED tissue kinetics. Our transporter affinity data may
provide an explanation for the observed kinetic behavior of 1R,2S [11C]HED
in human clinical studies as well as in an isolated rat heart model (DeGrado et
al., 1993). The neuronal accumulation of a neurotransmitter or a drug analog
is the net result of uptake, vesicular storage, and neuronal clearance processes
such as metabolism. 1R,2S HED and its stereoisomers incorporate a methyl
group α to the amino moiety (Fig. 1) which make these derivatives resistant
to metabolism by monoamine oxidase (MAO) present in sympathetic nerve
terminals. Additionally, due to its lower VMAT2 affinity as compared to
norepinephrine, 1R,2S [11C]HED is more likely than norepinephrine to dif-
fuse out of the neuron into the synapse where it can once again undergo
neuronal uptake by the NET. Thus, the extended tissue half-life of 1R,2S
[11C]HED may be explained by its tendency to undergo indefinite neuronal
recycling due to a combination of decreased metabolism, poor vesicular reten-
tion, and uptake via the NET. Given that all of the HED compounds are poor
substrates for MAO and have low affinity for VMAT2, their relative affinity
for the NET then becomes the dominant factor in neuronal recycling and
clearance. Due to its lower NET affinity and better overall selectivity among
all the monoamine uptake transporters (Table 1), the 1S,2R stereoisomer may
be a better choice than the 1R,2S isomer for compartmental modeling by PET
imaging.
In summary, there were modest but clear differences in potency among
the test drugs based upon the stereochemical configuration of the HED side-
chain. The 1R,2S HED stereoisomer was the preferred configuration at all the
plasma membrane transporters and at VMAT2. Although each of the four
monoamine carriers examined in this study is a unique protein, they all favor
1R,2S stereochemistry in substrate-like ligands, suggesting that the substrate
binding pockets within these transporters are at least grossly similar. Our data
also indicate that the 1S,2R HED isomer may be a better candidate for PET
imaging than the 1R,2S stereoisomer due to its lower NET and VMAT2
affinities and better overall selectivity for the NET compared to the DAT,
SERT, and VMAT2.
Acknowledgements
This work was supported in part by a grant from the National Alliance for Research on
Schizophrenia and Depression (NVC) and by NIH grant NS33560 (MKS). We thank J.
McKeel and M. Singer for their technical support.
Stereospecific inhibition of monoamine uptake transporters 1239
References
Allman KC, Stevens MJ, Wieland DM, Hutchins GD, Wolfe ERJ, Greene DA,
Schwaiger M (1993a) Noninvasive assessment of cardiac diabetic neuropathy by
carbon-11 hydroxyephedrine and positron emission tomography. J Am Coll Cardiol
22: 1425–1432
Allman KC, Wieland DM, Muzik O, Degrado TR, Wolfe ERJ, Schwaiger M (1993b)
Carbon-11 hydroxyephedrine with positron emission tomography for serial assess-
ment of cardiac adrenergic neuronal function after acute myocardial infarction in
humans. J Am Coll Cardiol 22: 368–375
Barker EL, Moore KR, Rakhshan F, Blakely RD (1999) Transmembrane domain i
contributes to the permeation pathway for serotonin and ions in the serotonin trans-
porter. J Neurosci 19: 4705–4717
Cozzi NV, Sievert MK, Shulgin AT, Jacob III P, Ruoho AE (1999) Inhibition of plasma
membrane monoamine transporters by -ketoamphetamines. Eur J Pharmacol 381:
63–69
Crespi D, Mennini T, Gobbi M (1997) Carrier-dependent and ca(2)-dependent 5-ht
and dopamine release induced by ()-amphetamine, 3,4-methylendioxymetham-
phetamine, p-chloroamphetamine and ()-fenfluramine. Br J Pharmacol 121: 1735–
1743
DeGrado TR, Hutchins GD, Toorongian SA, Wieland DM, Schwaiger M (1993) Myocar-
dial kinetics of carbon-11-meta-hydroxyephedrine: retention mechanisms and effects
of norepinephrine. J Nucl Med 34: 1287–1293
Di Carli MF, Tobes MC, Mangener T, Levine AB, Muzik O, Chakroborty P, Levine TB
(1997) Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J
Med 336: 1208–1215
Feany MB, Lee S, Edwards RH, Buckley KM (1992) The synaptic vesicle protein sv2 is a
novel type of transmembrane transporter. Cell 70: 861–867
Finn JPr, Edwards RH (1997) Individual residues contribute to multiple differences in
ligand recognition between vesicular monoamine transporters 1 and 2. J Biol Chem
272: 16301–16307
Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG (1992)
Cloning, pharmacological characterization, and chromosome assignment of the
human dopamine transporter. Mol Pharmacol 42: 383–390
Graham D, Langer SZ (1992) Advances in sodium-ion coupled biogenic amine transport-
ers. Life Sci 51: 631–645
Gu H, Wall SC, Rudnick G (1994) Stable expression of biogenic amine transporters
reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem
269: 7124–7130
Huang X, Marona-Lewicka D, Nichols DE (1992) P-methylthioamphetamine is a potent
new non-neurotoxic serotonin-releasing agent. Eur J Pharmacol 229: 31–38
Johnson RG (1987) Proton pumps and chemiosmotic coupling as a generalized mecha-
nism for neurotransmitter and hormone transport. Ann NY Acad Sci 493: 162–
177
Kanner BI (1994) Sodium-coupled neurotransmitter transport: structure, function and
regulation. J Exp Biol 196: 237–249
Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR (1992) Dopamine
transporter site-directed mutations differentially alter substrate transport and co-
caine binding. Proc Natl Acad Sci USA 89: 7782–7785
Liu Y, Peter D, Roghani A, Schuldiner S, Prive GG, Eisenberg D, Brecha N, Edwards
RH (1992) A cdna that suppresses mpp toxicity encodes a vesicular amine trans-
porter. Cell 70: 539–551
Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE (1993) Synthesis and phar-
macological examination of benzofuran, indan, and tetralin analogues of 3,4-
(methylenedioxy)amphetamine. J Med Chem 36: 3700–3706
1240 K. F. Foley et al.: Stereospecific inhibition of monoamine uptake transporters
Njus D (1983) The chromaffin vesicle and the energetics of storage organelles. J Auton
Nerv Syst 7: 35–40
Pacholczyk T, Blakely RD, Amara SG (1991) Expression cloning of a cocaine- and
antidepressant-sensitive human noradrenaline transporter. Nature 350: 350–354
Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M,
Wieland DM (1990) Synthesis and preliminary evaluation of carbon-11-meta-
hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J Nucl Med
31: 1328–1334
Rothman RB, Ayestas MA, Dersch CM, Baumann MH (1999) Aminorex, fenfluramine,
and chlorphentermine are serotonin transporter substrates. Implications for primary
pulmonary hypertension. Circulation 100: 869–875
Rudnick G (1998) Ion-coupled neurotransmitter transport: thermodynamic vs. kinetic
determinations of stoichiometry. Meth Enzymol 269: 233–247
Rudnick G, Clark J (1993) From synapse to vesicle: the reuptake and storage of biogenic
amine neurotransmitters. Biochim Biophys Acta 1144: 249–263
Rudnick G, Wall SC (1993) Non-neurotoxic amphetamine derivatives release serotonin
through serotonin transporters. Mol Pharmacol 43: 271–276
Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, Rudnick G (1993) Amphetamine
derivatives interact with both plasma membrane and secretory vesicle biogenic amine
transporters. Mol Pharmacol 44: 1227–1231
Schuldiner S, Shirvan A, Linial M (1995) Vesicular neurotransmitter transporters: from
bacteria to humans. Physiol Rev 75: 369–392
Schwaiger M, Kalff V, Rosenspire K, Haka MS, Molina E, Hutchins GD, Deeb M, Wolfe
EJ, Wieland DM (1990) Noninvasive evaluation of sympathetic nervous system in
human heart by positron emission tomography. Circulation 82: 457–464
Schwaiger M, Hutchins GD, Halff V, Rosenspire K, Haka MS, Mallette S, Deeb GM,
Abrams GD, Wieland D (1991) Evidence for regional catecholamine uptake and
storage sites in the transplanted human heart by positron emission tomography.
J Clin Invest 87: 1681–1690
Van Dort ME (1999) Direct chromatographic resolution and isolation of the four stere-
oisomers of meta-hydroxyphenylpropanolamine. Chirality 11: 684–688
Van Dort ME, Tluczek L (2000) Synthesis and carbon-11 labeling of the stereoisomers
of meta-hydroxyephedrine (hed) and meta-hydroxypseudoephedrine (hped). J
Labelled Cpd Radiopharm 43: 603–612
Worrall DM, Williams DC (1994) Sodium ion-dependent transporters for neurotransmit-
ters: a review of recent developments. Biochem J 297 (Pt 3): 425–436
Authors’ address: Dr. N. V. Cozzi, Department of Pharmacology, Brody School of
Medicine, East Carolina University, Greenville, NC 27858, U.S.A., e-mail:
cozzin@mail.ecu.edu
